76
Participants
Start Date
January 27, 2017
Primary Completion Date
January 11, 2018
Study Completion Date
March 29, 2018
Faricimab
Faricimab was administered via IVT injections as specified during the treatment period.
Ranibizumab
Ranibizumab was administered via IVT injections as specified during the treatment period.
Sham Procedure
The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
Vitreoretinal Consultants, Great Neck
The Retina Care Center, Baltimore
Southeast Retina Center, Augusta
Southern Vitreoretinal Assoc, Tallahassee
Florida Eye Associates, Melbourne
Rand Eye, Deerfield Beach
Retina Vitreous Assoc of FL, St. Petersburg
Charles Retina Institute, Germantown
Midwest Eye Institute, Indianapolis
Wolfe Eye Clinic, West Des Moines
Vitreo Retinal Surgery, Minneapolis
Texas Retina Associates, Arlington
Strategic Clinical Research Group, LLC, Willow Park
Retina Research Center, Austin
Retina Res Institute of Texas, Abilene
Retina Associates of Utah, Salt Lake City
Retinal Consultants of Arizona, Phoenix
Retina Associates Southwest PC, Tucson
Eye Associates of New Mexico, Albuquerque
Sierra Eye Associates, Reno
California Retina Consultants, Bakersfield
Retinal Diagnostic Center, Campbell
Retina Northwest, Portland
Oregon Retina, LLP, Eugene
Retina Consultants of Southern Colorado PC; Clinical Research Department, Colorado Springs
Hoffmann-La Roche
INDUSTRY